The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Sanovas' minimally invasive nested balloon catheter for localized drug delivery.
The patent will protect an integral part of the company's NanoVas drug delivery technology, designed for delivering diagnostic and therapeutic agents to small diameter anatomy in the lungs and throughout the body.
The catheter is a component of the company's Vas Zeppelin Smart Catheter technology portfolio, which features a small surgical camera to remove tumors and other obstructions and deliver drug and immune therapies, claims the company.
Sanovas founders Larry Gerrans said the ability to deliver customized immune and gene therapy will transform the way cancer and chronic disease are treated.
"Sanovas is proud to be at the forefront of these significant advances," Gerrans added.
Sanovas chief technology officer and co-founder Erhan Gunday said, "With more than 45 patents and patents pending, Sanovas has built a strong IP portfolio for our micro-invasive diagnostics, devices and drug delivery technologies that poise to significantly advance the way pulmonary diseases, such as lung cancer, are detected and treated."
